United Therapeutics Corporation (UTHR) Financial Ratios
28 years of historical data (1998–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
15.57
↑+24% vs avg
5yr avg: 12.54
30Y Low5.2·High83.0
P/FCF
↑
25.11
↑+33% vs avg
5yr avg: 18.92
30Y Low8.1·High67.8
P/B Ratio
↑
4.02
↑+53% vs avg
5yr avg: 2.63
30Y Low1.1·High11.5
ROE
↑
19.7%
↓+14% vs avg
5yr avg: 17.4%
30Y Low-95%·High45%
Debt/EBITDA
↓
N/A
—
5yr avg: 0.72
30Y Low0.0·High34.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
UTHR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
United Therapeutics Corporation trades at 21.4x earnings, 29% above its 5-year average of 16.6x, sitting at the 65th percentile of its historical range. This is roughly in line with the Healthcare sector median P/E of 22.1x. On a free-cash-flow basis, the stock trades at 25.1x P/FCF, 33% above the 5-year average of 18.9x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $26.1B | $23.3B | $17.1B | $10.9B | $13.5B | $10.2B | $6.8B | $3.9B | $4.8B | $6.6B | $6.7B |
| Enterprise Value | $24.6B | $21.8B | $15.7B | $10.4B | $13.3B | $10.1B | $6.8B | $4.0B | $4.4B | $6.2B | $5.7B |
| P/E Ratio → | 21.40 | 17.49 | 14.32 | 11.10 | 18.54 | 21.48 | 13.15 | — | 8.13 | 15.89 | 9.41 |
| P/S Ratio | 8.21 | 7.33 | 5.95 | 4.70 | 6.97 | 6.06 | 4.56 | 2.66 | 2.94 | 3.85 | 4.20 |
| P/B Ratio | 4.02 | 3.29 | 2.66 | 1.83 | 2.81 | 2.58 | 1.99 | 1.39 | 1.72 | 3.16 | 3.60 |
| P/FCF | 25.11 | 22.43 | 15.84 | 14.62 | 20.32 | 21.41 | 9.72 | — | 8.07 | 17.13 | 11.18 |
| P/OCF | 16.74 | 14.95 | 12.89 | 11.17 | 16.81 | 17.09 | 8.96 | — | 6.16 | 14.01 | 10.43 |
P/E links to full P/E history page with 30-year chart
UTHR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
United Therapeutics Corporation's enterprise value stands at 15.6x EBITDA, 24% above its 5-year average of 12.5x. The Healthcare sector median is 14.1x, placing the stock at a 10% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.84 | 5.46 | 4.48 | 6.88 | 6.01 | 4.61 | 2.74 | 2.69 | 3.59 | 3.56 |
| EV / EBITDA | 15.57 | 13.80 | 10.84 | 8.42 | 12.93 | 16.71 | 10.62 | — | 5.20 | 7.32 | 5.20 |
| EV / EBIT | 16.46 | 12.57 | 9.93 | 7.81 | 13.47 | 14.74 | 11.45 | — | 5.45 | 6.05 | 5.37 |
| EV / FCF | — | 20.93 | 14.54 | 13.94 | 20.08 | 21.21 | 9.81 | — | 7.36 | 15.95 | 9.48 |
UTHR Profitability
Margins and return-on-capital ratios measuring operating efficiency
United Therapeutics Corporation earns an operating margin of 46.9%. Operating margins have compressed from 50.9% to 46.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 19.7% indicates solid capital efficiency. ROIC of 21.1% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.9% | 87.9% | 89.2% | 88.9% | 92.4% | 92.7% | 92.7% | 91.9% | 87.8% | 93.9% | 95.5% |
| Operating Margin | 46.9% | 46.9% | 47.9% | 50.9% | 50.6% | 33.0% | 40.0% | -12.9% | 49.5% | 47.2% | 66.4% |
| Net Profit Margin | 41.9% | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | 34.7% | -7.2% | 36.2% | 24.2% | 44.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 19.7% | 19.7% | 19.2% | 18.3% | 16.6% | 12.9% | 16.7% | -3.8% | 24.1% | 21.1% | 41.2% |
| ROA | 17.5% | 17.5% | 16.4% | 14.9% | 13.0% | 9.7% | 12.1% | -2.9% | 18.8% | 16.1% | 31.6% |
| ROIC | 21.1% | 21.1% | 19.6% | 17.6% | 17.3% | 11.4% | 14.0% | -5.3% | 30.1% | 49.2% | 98.8% |
| ROCE | 21.4% | 21.4% | 21.2% | 19.6% | 18.5% | 12.1% | 15.3% | -5.7% | 29.0% | 36.8% | 56.8% |
UTHR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $1.6B exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 88.9x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.05 | 0.12 | 0.17 | 0.20 | 0.24 | 0.31 | 0.09 | 0.12 | — |
| Debt / EBITDA | — | — | 0.21 | 0.57 | 0.78 | 1.32 | 1.24 | — | 0.30 | 0.30 | — |
| Net Debt / Equity | — | -0.22 | -0.22 | -0.08 | -0.03 | -0.02 | 0.02 | 0.04 | -0.15 | -0.22 | -0.55 |
| Net Debt / EBITDA | -0.99 | -0.99 | -0.96 | -0.41 | -0.16 | -0.16 | 0.10 | — | -0.50 | -0.54 | -0.94 |
| Debt / FCF | — | -1.50 | -1.29 | -0.68 | -0.24 | -0.20 | 0.09 | — | -0.71 | -1.17 | -1.70 |
| Interest Coverage | 88.89 | 88.89 | 36.87 | 22.49 | 30.52 | 36.93 | 25.38 | -2.73 | 57.73 | 113.60 | 271.59 |
Net cash position: cash ($1.6B) exceeds total debt ($0)
UTHR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
United Therapeutics Corporation's current ratio of 6.60x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 6.28x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 4.41x to 6.60x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.60 | 6.60 | 5.25 | 4.41 | 9.85 | 7.61 | 6.70 | 4.03 | 6.39 | 3.26 | 4.29 |
| Quick Ratio | 6.28 | 6.28 | 5.03 | 4.28 | 9.55 | 7.30 | 6.44 | 3.83 | 6.03 | 3.01 | 3.98 |
| Cash Ratio | 2.78 | 2.78 | 4.43 | 3.72 | 8.27 | 6.32 | 5.68 | 3.21 | 5.12 | 2.09 | 3.16 |
| Asset Turnover | — | 0.40 | 0.39 | 0.32 | 0.32 | 0.33 | 0.32 | 0.37 | 0.48 | 0.60 | 0.69 |
| Inventory Turnover | 2.10 | 2.10 | 1.96 | 2.30 | 1.44 | 1.31 | 1.25 | 1.26 | 1.97 | 0.98 | 0.73 |
| Days Sales Outstanding | — | 40.16 | 35.43 | 43.74 | 41.55 | 43.03 | 38.73 | 38.14 | 39.40 | 62.85 | 48.97 |
UTHR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
United Therapeutics Corporation returns 3.8% to shareholders annually primarily through share buybacks. The earnings yield of 4.7% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.7% | 5.7% | 7.0% | 9.0% | 5.4% | 4.7% | 7.6% | — | 12.3% | 6.3% | 10.6% |
| FCF Yield | 4.0% | 4.5% | 6.3% | 6.8% | 4.9% | 4.7% | 10.3% | — | 12.4% | 5.8% | 8.9% |
| Buyback Yield | 3.8% | 4.3% | 5.9% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.0% | 3.8% | 7.4% |
| Total Shareholder Yield | 3.8% | 4.3% | 5.9% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.0% | 3.8% | 7.4% |
| Shares Outstanding | — | $48M | $49M | $50M | $49M | $47M | $45M | $44M | $44M | $45M | $47M |
Peer Comparison
Compare UTHR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 UTHRYou | $26B | 21.4 | 15.6 | 25.1 | 87.9% | 46.9% | 19.7% | 21.1% | — |
 IDYA | $3B | -22.5 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
 RARE | $3B | -4.4 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 ACAD | $4B | 9.4 | 25.6 | 35.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PTGX | $7B | -50.7 | — | 118.3 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 INVA | $2B | 6.8 | 8.0 | 9.8 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 HALO | $8B | 25.9 | 8.5 | 12.1 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 MNKD | $1B | 178.0 | 29.3 | 80.3 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 LNTH | $6B | 25.3 | 13.8 | 15.8 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 INSM | $29B | -21.4 | — | — | 79.7% | -205.6% | -249.3% | -141.8% | — |
 LGND | $5B | -1057.0 | 356.7 | 59.1 | 93.4% | -13.5% | -0.5% | -2.3% | 0.6 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 28 years · Updated daily
Full UTHR Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See UTHR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs UTHR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare UTHR vs IDYA
Side-by-side business, growth, and profitability comparison vs IDEAYA Biosciences, Inc..
Start ComparisonUTHR — Frequently Asked Questions
Quick answers to the most common questions about buying UTHR stock.
What is United Therapeutics Corporation's P/E ratio?
United Therapeutics Corporation's current P/E ratio is 21.4x. The historical average is 31.5x. This places it at the 65th percentile of its historical range.
What is United Therapeutics Corporation's EV/EBITDA?
United Therapeutics Corporation's current EV/EBITDA is 15.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 21.0x.
What is United Therapeutics Corporation's ROE?
United Therapeutics Corporation's return on equity (ROE) is 19.7%. The historical average is 5.3%.
Is UTHR stock overvalued?
Based on historical data, United Therapeutics Corporation is trading at a P/E of 21.4x. This is at the 65th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are United Therapeutics Corporation's profit margins?
United Therapeutics Corporation has 87.9% gross margin and 46.9% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.